HOME > TOP STORIES

TOP STORIES

BUSINESS Actelion’s Flolan Generic Outstrips Originator in Pediatric Use with Rare Dosage Nod; Japan Chief Says Company Fulfilling Maker’s Responsibility

April 6, 2017
INTERVIEW Scohia Wants to Make Its “Carve Out” a Success Model for Japan Makers: CEO

April 5, 2017
REGULATORY “I Don’t Use Biosimilars,” Says Ex-Chief of Japan College of Rheumatology

April 5, 2017
REGULATORY MHLW Sets Up Office for Startup Support, Starts Receiving Applications for Consultations

April 4, 2017
BUSINESS EA Pharma Eager to Roll Out Several New Drugs in Next Couple of Years

April 3, 2017
TRENDS Mitsubishi Tanabe’s Exit Shows Research-Driven Makers’ Generic Biz at Crossroads

March 31, 2017
BUSINESS Tokyo Prosecutors File Appeal in Diovan Case

March 30, 2017
BUSINESS Mitsubishi Tanabe to Pull Plug on Generics, Transfer Biz to Nipro in October

March 29, 2017
ORGANIZATION Wholesalers to Address Product Return Issue after Fake Harvoni Case: JPWA Chair

March 28, 2017
ORGANIZATION Vaccine Association to Standardize Presentation of Expiration Dates above Inspection Dates on Outer Packaging

March 27, 2017
BUSINESS Wholesale Dealer President Deeply Sorry for Letting Fake Harvoni into Supply Chain

March 24, 2017
TRENDS As Takeda’s R&D Rejig Progresses, Biotech JV Launch Sets Direction for Its Japan Regime

March 23, 2017
BUSINESS Japan Begins Using PD-L1 Expression Biomarker for Immune Checkpoint Inhibitors, but Challenges Linger

March 22, 2017
ORGANIZATION Study Group Presents Proposal for Future Vision for Kampo Medicines

March 21, 2017
BUSINESS Court Finds Data Manipulation, but Not False Advertising: Diovan Case

March 17, 2017
BUSINESS Novartis, Ex-Employee Found Not Guilty in Diovan Case

March 16, 2017
REGULATORY Chuikyo Begins Debate on Gap-Year Price Revisions; Industry Frets Advance Announcement of Discrepancy Threshold

March 16, 2017
BUSINESS Takeda Biotech JV to Focus on 8 Projects for Now, Eyes IPO: CEO Okumura

March 15, 2017
REGULATORY Celgene Faces Biz Improvement Order over Delays in Side Effect Reporting

March 15, 2017
BUSINESS INCJ, Takeda, Medipal to Form Biotech Venture

March 14, 2017

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…